These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1117 related articles for article (PubMed ID: 23466307)

  • 1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
    Sangro B; Gomez-Martin C; de la Mata M; Iñarrairaegui M; Garralda E; Barrera P; Riezu-Boj JI; Larrea E; Alfaro C; Sarobe P; Lasarte JJ; Pérez-Gracia JL; Melero I; Prieto J
    J Hepatol; 2013 Jul; 59(1):81-8. PubMed ID: 23466307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
    J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facing the dawn of immunotherapy for hepatocellular carcinoma.
    Sprinzl MF; Galle PR
    J Hepatol; 2013 Jul; 59(1):9-10. PubMed ID: 23571018
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity.
    Galun E; Terrault NA; Eren R; Zauberman A; Nussbaum O; Terkieltaub D; Zohar M; Buchnik R; Ackerman Z; Safadi R; Ashur Y; Misrachi S; Liberman Y; Rivkin L; Dagan S
    J Hepatol; 2007 Jan; 46(1):37-44. PubMed ID: 17112624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease.
    Tokita H; Murai S; Kamitsukasa H; Yagura M; Harada H; Takahashi M; Okamoto H
    J Med Virol; 2002 Aug; 67(4):501-9. PubMed ID: 12115995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.
    Shindoh J; Hasegawa K; Matsuyama Y; Inoue Y; Ishizawa T; Aoki T; Sakamoto Y; Sugawara Y; Makuuchi M; Kokudo N
    J Clin Oncol; 2013 Feb; 31(6):766-73. PubMed ID: 23129744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the inhibitory effect of antisense oligodeoxynucleotides on the growth of hepatitis C-associated hepatocellular carcinoma cells in vitro.
    Amin MA; Awadein MR; Gabr H
    Chin J Dig Dis; 2005; 6(3):142-8. PubMed ID: 16045605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.
    Bernardinello E; Cavalletto L; Chemello L; Mezzocolli I; Donada C; Benvegnú L; Merkel C; Gatta A; Alberti A
    Hepatogastroenterology; 1999; 46(30):3216-22. PubMed ID: 10626189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.
    Tomova R; Antonov K; Ivanova A; Jacobs JJ; Koten JW; Den Otter W; Krastev Z
    Anticancer Res; 2009 Dec; 29(12):5241-4. PubMed ID: 20044643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of TT virus infection in patients with chronic hepatitis C.
    Zein NN; Arslan M; Li H; Charlton MR; Gross JB; Poterucha JJ; Therneau TM; Kolbert CP; Persing DH
    Am J Gastroenterol; 1999 Oct; 94(10):3020-7. PubMed ID: 10520863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma.
    Ikeda A; Shimizu T; Matsumoto Y; Fujii Y; Eso Y; Inuzuka T; Mizuguchi A; Shimizu K; Hatano E; Uemoto S; Chiba T; Marusawa H
    Gastroenterology; 2014 Jan; 146(1):222-32.e35. PubMed ID: 24055508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.